BR112022017557A2 - Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal - Google Patents

Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal

Info

Publication number
BR112022017557A2
BR112022017557A2 BR112022017557A BR112022017557A BR112022017557A2 BR 112022017557 A2 BR112022017557 A2 BR 112022017557A2 BR 112022017557 A BR112022017557 A BR 112022017557A BR 112022017557 A BR112022017557 A BR 112022017557A BR 112022017557 A2 BR112022017557 A2 BR 112022017557A2
Authority
BR
Brazil
Prior art keywords
stem cells
inflammatory lung
lung diseases
treat inflammatory
line precursor
Prior art date
Application number
BR112022017557A
Other languages
English (en)
Portuguese (pt)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900685A external-priority patent/AU2020900685A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022017557A2 publication Critical patent/BR112022017557A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112022017557A 2020-03-05 2021-03-04 Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal BR112022017557A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020900685A AU2020900685A0 (en) 2020-03-05 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
PCT/EP2021/055483 WO2021176001A1 (en) 2020-03-05 2021-03-04 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
BR112022017557A2 true BR112022017557A2 (pt) 2022-12-27

Family

ID=74867509

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017557A BR112022017557A2 (pt) 2020-03-05 2021-03-04 Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal

Country Status (9)

Country Link
US (1) US20230293589A1 (enExample)
EP (1) EP4114418B1 (enExample)
JP (1) JP2023517035A (enExample)
KR (1) KR20220150919A (enExample)
CN (1) CN115361958A (enExample)
AU (1) AU2021232614A1 (enExample)
BR (1) BR112022017557A2 (enExample)
CA (1) CA3170255A1 (enExample)
WO (1) WO2021176001A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4663241A3 (en) 2010-10-08 2026-03-25 Mesoblast International Sàrl Enhanced msc preparations
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I
IL299997A (en) * 2020-07-20 2023-03-01 Brainstorm Cell Therapeutics Ltd Methods and preparations for the treatment of lung conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
EP2298863B1 (en) * 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP4663241A3 (en) * 2010-10-08 2026-03-25 Mesoblast International Sàrl Enhanced msc preparations
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
CN105796598A (zh) * 2014-12-29 2016-07-27 西比曼生物科技（上海）有限公司 一种用于治疗慢性阻塞性肺疾病的脂肪间充质祖细胞复合物
CN110139657A (zh) * 2017-02-15 2019-08-16 日本乐敦制药株式会社 肺纤维化治疗剂、ptprr表达促进剂及肺纤维化治疗用试剂盒
CL2017002357A1 (es) * 2017-09-16 2018-04-20 Cells For Cells S A Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
CN111297899A (zh) * 2020-02-21 2020-06-19 云南雅盛医疗科技有限公司 一种脐带间充质干细胞在制备治疗新型冠状肺炎药物中的应用

Also Published As

Publication number Publication date
WO2021176001A1 (en) 2021-09-10
AU2021232614A1 (en) 2022-09-29
EP4114418A1 (en) 2023-01-11
CA3170255A1 (en) 2021-09-10
KR20220150919A (ko) 2022-11-11
JP2023517035A (ja) 2023-04-21
EP4114418B1 (en) 2026-05-20
US20230293589A1 (en) 2023-09-21
CN115361958A (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
BR112022020042A2 (pt) Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
AR081450A1 (es) Tratamiento de sarcoidosis usando celulas madre de placenta
CO2020010342A2 (es) Composiciones de arni de 17 β -hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas
BR112017027411A2 (pt) inibidores de nadph oxidase 4
MX339658B (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa.
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112022017560A2 (pt) Método para tratar doença inflamatória intestinal i
BR112022007721A2 (pt) Método para o tratamento da demência
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
BR112021020525A2 (pt) Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
BR112015019197A2 (pt) tratamento de doença de enxerto versus hospedeiro em pacientes transplantados
BR112014016950A8 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
BR112023021840A2 (pt) Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
BR112022020392A2 (pt) Método para tratar um indivíduo que tem doença de huntington, inibidor do bromodomínio 9, e, uso de um inibidor do bromodomínio 9
BR112023026559A2 (pt) Formas cristalinas de trofinetida
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.
BR112022014456A2 (pt) Tafoxiparina para o tratamento da pré-eclâmpsia
BR112019007259A2 (pt) recipiente de câmara dupla adequado para uso com um nebulizador e pré-carregado com uma composição nebulizável, kit, composição nebulizável, solução nebulizável aquosa, método para administrar de tiotrópio e formoterol a um paciente com necessidade do mesmo e método para preparar um nebulizador
BR112022022204A2 (pt) Usos e formulações de canabinoides